| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA925: Mirikizumab for treating moderately to severely active ulcerative colitis |
|
Medicine details |
|
| Medicine name | mirikizumab (Omvoh®) |
| Formulation | subcutaneous injection |
| Reference number | 4049 |
| Indication | Treatment of moderate-to-severe active ulcerative colitis in adults after failed previous therapy |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/08/2023 |
| NICE guidance | TA925: Mirikizumab for treating moderately to severely active ulcerative colitis |